Prospective Non-randomised Exploratory Study to Assess the Safety and Efficacy of Aflibercept (Eylea) in Cystoid Macular Oedema (CMO) Associated With Retinitis Pigmentosa (RP)

Trial Profile

Prospective Non-randomised Exploratory Study to Assess the Safety and Efficacy of Aflibercept (Eylea) in Cystoid Macular Oedema (CMO) Associated With Retinitis Pigmentosa (RP)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Retinal oedema
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AMOUR
  • Most Recent Events

    • 13 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 02 Jun 2016 New source identified and integrated (European Clinical Trials Database EudraCT2015-003723-65).
    • 21 Mar 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top